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Abstract
Background
Preventive chemotherapy with praziquantel (PZQ) is the cornerstone of schistosomiasis
control. However, a single dose of PZQ (40 mg/kg) does not cure all infections. Repeated
doses of PZQ at short intervals might increase efficacy in terms of cure rate (CR) and inten-
sity reduction rate (IRR). Here, we determined the efficacy of a single versus four repeated
treatments with PZQ on Schistosoma mansoni infection in school-aged children from Coˆte
d’Ivoire, using two different diagnostic tests.
Methods
An open-label, randomized controlled trial was conducted from October 2018 to January
2019. School-aged children with a confirmed S. mansoni infection based on Kato-Katz (KK)
and point-of-care circulating cathodic antigen (POC-CCA) urine cassette test were ran-
domly assigned to receive either a single or four repeated doses of PZQ, administered at
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two-week intervals. The primary outcome was the difference in CR between the two treat-
ment arms, measured by triplicate KK thick smears 10 weeks after the first treatment. Sec-
ondary outcomes included CR estimated by POC-CCA, IRR by KK and POC-CCA, and
safety of repeated PZQ administration.
Principal findings
During baseline screening, 1,022 children were assessed for eligibility of whom 153 (15%)
had a detectable S. mansoni infection, and hence, were randomized to the standard treat-
ment group (N = 70) and the intense treatment group (N = 83). Based on KK, the CR was
42% (95% confidence interval (CI) 31–52%) in the standard treatment group and 86% (95%
CI 75–92%) in the intense treatment group. Observed IRR was 72% (95% CI 55–83%) in
the standard treatment group and 95% (95% CI 85–98%) in the intense treatment group.
The CR estimated by POC-CCA was 18% (95% CI 11–27%) and 36% (95% CI 26–46%) in
the standard and intense treatment group, respectively. Repeated PZQ treatment did not
result in a higher number of adverse events.
Conclusion/significance
The observed CR using KK was significantly higher after four repeated treatments com-
pared to a single treatment, without an increase in adverse events. Using POC-CCA, the
observed CR was significantly lower than measured by KK, indicating that PZQ may be con-
siderably less efficacious as concluded by KK. Our findings highlight the need for reliable
and more accurate diagnostic tools, which are essential for monitoring treatment efficacy,
identifying changes in transmission, and accurately quantifying the intensity of infection in
distinct populations. In addition, the higher CR in the intense treatment group suggests that
more focused and intense PZQ treatment can help to advance schistosomiasis control.
Trial registration
www.clinicaltrials.gov NCT02868385.
Author summary
The previously established efficacy of the widely used drug praziquantel (PZQ) against
schistosomiasis might have been overestimated due to the use of inaccurate diagnostic
methods. Repeated PZQ treatment at short intervals in areas with ongoing transmission
could more effectively target non-susceptible schistosomula as they will have matured
into drug susceptible worms within a few weeks. In the current study, we aimed to deter-
mine the cure rate (CR) of repeated PZQ, measured by the Kato-Katz (KK) technique and
the point-of-care circulating cathodic antigen (POC-CCA) test, respectively. An open-
label, randomized controlled trial was conducted assigning 153 school-aged children with
a confirmed Schistosoma mansoni infection to two groups, one receiving a single PZQ
treatment, while the second group received four repeated PZQ treatments, given at two-
week intervals. Based on the KK test, the CR was significantly higher after four repeated
treatments compared to a single treatment. When using POC-CCA, a diagnostic method
that has not been utilized before in studies assessing the efficacy of four repeated PZQ
treatments, the CR was much lower, even after four repeated PZQ treatments. Our results
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indicate that worms are still present after multiple PZQ treatments and that PZQ might be
less efficacious than previously published.
Introduction
Schistosomiasis remains a public health problem in different parts of the world with an esti-
mated 779 million people at risk of infection and more than 250 million people infected [1, 2].
The disease is caused by parasitic blood flukes of the genus Schistosoma. The three most
important species are S. japonicum and S. mansoni (causing intestinal schistosomiasis) and S.
haematobium (causing urogenital schistosomiasis) [3, 4]. To control schistosomiasis, health
authorities rely on preventive chemotherapy, that is the large-scale administration of the
anthelmintic drug praziquantel (PZQ) to at risk populations without prior diagnosis [5]. This
strategy has been successful in reducing the prevalence and, most importantly, the intensity of
infection, and thereby controlling morbidity [6, 7]. The burden of schistosomiasis is greatest
in school-aged children, generally presenting the highest prevalence and intensity of infection
[8]. School-aged children are therefore the main target for preventive chemotherapy, consist-
ing of a single 40 mg/kg oral dose of PZQ, as recommended by the World Health Organization
(WHO) [5, 9, 10]. PZQ is the drug of choice because it is safe and efficacious against the adult
stages of all Schistosoma species [11]. The efficacy of PZQ is typically expressed as a cure rate
(CR) and often also as an intensity reduction rate (IRR), both based on pre- and post-treat-
ment data. Reported CRs in school-aged children range between 42% and 79% for S. mansoni
and between 37% and 93% for S. haematobium after a single 40 mg/kg oral dose of PZQ [12–
14]. Following a closely spaced second dose of PZQ, considerably higher CRs are reported;
91% for S. mansoni [12, 15, 16] and 99% for S. haematobium [12].
Most studies reporting on the efficacy of PZQ have used microscopy-based methods, such
as urine filtration for S. haematobium and the stool-based Kato-Katz (KK) technique for S.
japonicum and S. mansoni. However, these methods lack sensitivity, especially for detection of
low-intensity infections [17, 18]. Hence, reported CRs based on these parasitological methods
are likely an overestimation [19, 20]. From a public health perspective, the absence or a signifi-
cant reduction in the number of Schistosoma eggs is essential as they are causing morbidity
and keep transmission ongoing. However, from an individual health care perspective, worm
absence (cure) is more important. It is known that PZQ targets adult worms, therefore a direct
determination of PZQ efficacy would be to measure the number of worms instead of eggs
(which are usually used as a proxy for worm burden) with a highly accurate diagnostic tool.
The field-applicable and commercially available point-of-care circulating cathodic antigen
(POC-CCA) urine test, which identifies active worm infections by detection of schistosome
CCA in urine, has shown a higher sensitivity for detecting S. mansoni infections than the KK
technique [20–22]. It is now being recommended for surveillance and mapping of prevalence
of intestinal schistosomiasis [10, 18, 21, 23].
In addition to the possible overestimation of CRs due to insensitive diagnostic tools, the
limited activity of PZQ on immature worms as well as continuing reinfection might have led
to an underestimation of the efficacy [24–27]. Furthermore, the short metabolic half-life of
PZQ might also limit its effectivity [28]. In areas with ongoing transmission, where repeated
infections and hence the presence of schistosomula in the human body is likely, repeating
PZQ treatment a few weeks after the first dose might increase its overall effectiveness for para-
sitological cure [12, 29].
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In the current study, we assessed the effect of multiple doses of PZQ on parasite clearance
and tolerance in school-aged children from Coˆte d’Ivoire with a confirmed S. mansoni infec-
tion. As primary outcome we determined the difference in CR of a single versus four repeated
doses of PZQ, measured by the KK technique in stool samples 10 weeks after the first treat-
ment. Secondary outcomes included CR measured by the POC-CCA test, IRR by KK and
POC-CCA, and safety of repeated PZQ treatments. Given the paucity of highly effective con-
trol measures for schistosomiasis, the results of our study are essential to assess the most opti-
mal PZQ strategy from a public health control and best-care perspective.
Methods
Ethics statement
Ethics approval was obtained from the Comite´ National d’E´thique des Sciences de la Vie et de
la Sante´ de Coˆte d’Ivoire (CNESVS; reference no. 091-18/MSHP/CNESVS-km, date of
approval 27 June 2018), the Direction de la Pharmacie, du Me´dicament et des Laboratoires de
Coˆte d’Ivoire (DPML; reference no. 99433/MSPH/DGS/DPML/DAR and clinical trial number
ECCI00618, date of approval 22 October 2018), and the Ethics Committee of the Leiden Uni-
versity Medical Center in the Netherlands (P16.254, date of approval 11 January 2017). Com-
munities and health authorities were informed on the purpose and procedures of the study.
Participating children were informed about the objectives, procedures, and potential risks and
benefits of the study using lay terms. Written informed consent was obtained from children’s
parents or guardians, while children provided oral assent. The trial is registered at Clinical-
Trials.gov (registration no. NCT02868385).
Study design and participants
We conducted an open-label, randomized controlled trial with two arms in which children
aged 5–17 years from three villages located in the Taabo health district in south-central Coˆte
d’Ivoire [30] were included.
The trial was conducted from October 1, 2018 to January 14, 2019. In the first month of the
study (October 2018), children were assessed for eligibility during a baseline screening. Chil-
dren who were found positive for S. mansoni by KK and POC-CCA and egg-negative for S.
haematobium by urine filtration were eligible. A detailed description of the inclusion and
exclusion criteria is provided in the study protocol published elsewhere [31].
Eligible children were randomized into the ‘standard treatment’ group, receiving a single
PZQ treatment at baseline, or the ‘intense treatment’ group, receiving PZQ treatment at base-
line and again at two, four, and six weeks after the initial dose, totalling four treatments with
two-week intervals in the intense treatment group. Due to logistic reasons and school holidays,
final sample collection had to be postponed from 8 weeks (as described in the study protocol
[31]) to 10 weeks after baseline treatment (see S1 Fig).
Randomization and masking
Eligible school-aged children were randomly assigned to the standard or intense treatment
group, as described elsewhere [31]. Participants as well as nurses and the study physician were
not blinded to the treatment assignments, while laboratory technicians and investigators were
blinded to the treatment assignments.
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Outcomes
The primary outcome was the difference in CR of a single versus four repeated PZQ treat-
ments, based on KK in the intention-to-treat population. CR was defined as the proportion of
children being S. mansoni egg-positive at baseline who became egg-negative 10 weeks after the
first treatment. Secondary outcomes included the S. mansoni infection percentage positivity
and intensity over time based on KK and POC-CCA, the CR based on POC-CCA, the IRR
(defined as the percentage reduction in the median intensity, either expressed by eggs per
gram of stool (EPG) or by visual score of the POC-CCA, of the positive individuals, 10 weeks
after the first treatment, based on KK and POC-CCA, and safety of a single or multiple doses
of PZQ).
Procedures
Detailed descriptions of field and laboratory procedures are provided in the published study
protocol [31]. In brief, during the baseline survey, single urine and single stool samples were
collected from each participating child. Urine samples were subjected to POC-CCA (batch
#170522062; Rapid Medical Diagnostics, Pretoria, South Africa) using the semi-quantitative
scoring method called ‘G-scores’ [32]. With this POC-CCA batch, the provided quality control
(QC) standard-series S0, S1, S2, and S3 resulted in a G1, G4, G8, and G10, respectively (see stan-
dard operating procedure (SOP), provided as an appendix in Casacuberta-Partal et al. [32]). To
exclude the most abundant S. haematobium infections, urine filtration was performed on single
baseline urine samples. Stool samples were processed using the KK technique with triplicate
41.7 mg thick smears prepared from each sample, as described previously [31, 33].
To assess treatment efficacy, additional urine and stool samples were collected from each
participating child weekly and two-weekly, respectively, at eight time points over a period of
10 weeks. At each time point, all urine and stool samples were subjected to POC-CCA and KK,
respectively, as described above.
Treatment and monitoring of adverse events
At baseline, all included children were given PZQ (600 mg tablets; Biltricide, Bayer, Abidjan,
Coˆte d’Ivoire), according to the calculated dose per kg of bodyweight (40 mg/kg, weight mea-
sured by a Seca 877 digital scale). Prior to treatment, breakfast was provided to each child.
After sample collection, directly observed treatment was applied by the study physician and
was accompanied with water and lunch, provided by the research team. Children allocated to
the intense treatment group were re-treated with PZQ at 2, 4, and 6 weeks after the first
treatment.
After treatment, children remained under medical supervision for at least 3 hours and
adverse events were recorded. If needed, symptomatic treatment for adverse events was pro-
vided by the study physician. In case vomiting occurred within 1.5 hours, children were re-
administered a dose of PZQ. Twenty-four hours post-treatment, children were interviewed
about the occurrence of adverse events. An adverse event was defined as any undesirable sign,
symptom, or disease occurring to a participant during the study, whether or not related to
PZQ treatment. Intensity of adverse events was graded by the study physician as mild, moder-
ate, or severe, following guidelines by the European Medicine Agency.
Statistical analysis
A detailed description of the sample size calculation is given elsewhere [31]. In brief, to detect
an increase in CR from 66% after a single PZQ treatment [12] to 99% after four repeated PZQ
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treatments with a two-sided 5% significance level and a power of 90%, a minimum sample size
of 30 children per group was required [31, 34]. To account for follow-up losses, expected due
to the intense weekly follow-up, the sample size was increased to 100 children in each group,
hence 200 children in total. Assuming a S. mansoni infection prevalence of approximately 25%
based on KK (Taabo health and demographic surveillance site survey carried out in February
2016), at least 1,000 children needed to be screened in order to obtain a minimum of 200 KK-
positive children in the Taabo region.
Data were double entered by two well-trained data entry clerks and managed using a RED-
Cap electronic data capture tool hosted at Leiden University Medical Center (Leiden, the
Netherlands), via Emory University (Atlanta, United States of America) [35, 36]. Descriptive
statistics were performed using IBM Statistical Package for Social Sciences version 25 (SPSS
Inc., Chicago, United States of America).
Infection intensity, as expressed by EPG, was calculated by multiplying the sum of egg
counts from triplicate KK thick smears by a factor of 8. Intensity of infection was classified
according to WHO guidelines into light (1–99 EPG), moderate (100–399 EPG), and heavy
(�400 EPG) [5]. POC-CCA G-scores were classified into negative (G1), trace (G2-3, conserva-
tively considered as negative in the analysis presented here), 1+ (G4-5), 2+ (G6-7), or 3+ (G8-
10) [10, 22, 32, 37].
To determine the prevalence over time as well as CRs (based on KK and POC-CCA) and
IRRs (based on KK), mixed effects models were employed to take into account the correlation
between the different measurements from the same individual [38–40]. For the prevalence, we
used mixed effects logistic regression where prevalence was modeled as a function of time,
treatment group and their interaction. In the case of KK, the time variable was taken as cate-
gorical, while for POC-CCA we modeled progression over time using natural cubic splines
with four knots. For the KK-based IRR, we used a zero-inflated negative binomial mixed
model where the logarithm of the mean egg counts is modeled as a function of time (using nat-
ural cubic splines), treatment group and their interaction. For POC-CCA, the IRRs could not
be obtained from the mixed effects model, as the output (G-score) is not a continuous variable.
Therefore, the IRR based on POC-CCA was calculated according to WHO guidelines (1 −
[arithmetic mean after treatment/arithmetic mean before treatment]) × 100 [41]. In all models,
the within subject correlation was modeled using a random intercepts term. The models used
provide results under the missing at random assumption for the missing data which is valid in
this study. All analyses were done in R (version 3.43) using the GLMMadaptive package. CR
and IRR estimated from the model are given with their corresponding 95% pointwise confi-
dence intervals (CIs). P-values <0.05 were considered to indicate statistical significance.
Results
Fig 1 shows the study flow. At baseline, 1,022 children aged 5–17 years were assessed for eligi-
bility. Of these, 153 had a detectable S. mansoni infection and met the inclusion criteria. They
were randomly assigned to one of the two study arms; 70 were assigned to the standard treat-
ment group, and 83 were assigned to the intense treatment group. Regular randomization was
performed instead of block randomization, and hence, the size of the two groups differed. At
baseline, all 153 children (100%) received treatment. Three children (one in the standard treat-
ment group and two in the intense treatment group) were lost to follow-up from week 6
onwards because they moved out of the study region during the follow-up period (see S1
Table). In the intense treatment group, compliance to each following treatment was unexpect-
edly high, from 100% in week 2 (second treatment) to 98% in week 6 (fourth and final treat-
ment). All 153 children were included in the intention-to-treat analysis.
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The demographic and parasitological baseline data for the participating children are
summarized in Table 1. The median age and sex of children were balanced among the two
groups. In both groups, most of the children had a light to moderate S. mansoni infection,
while heavy infection intensities were observed in 18 (26%) children in the standard treat-
ment group compared to 12 (14%) children in the intense treatment group. At pre-treat-
ment, the median fecal egg count was 172 EPG and the median G-score in urine was 6 in
the standard treatment group, and 128 EPG and G-score 7 in the intense treatment group,
respectively.
Prevalence over time
Fig 2 illustrates the percentage of S. mansoni positives over time based on KK (Fig 2A) and on
POC-CCA (Fig 2B). In the standard treatment group, the overall S. mansoni prevalence based
on triplicate KK thick smears was decreased from 100% to 58% (95% CI 48–68%), measured
10 weeks after treatment. In the intense treatment group, who received a total of four doses of
PZQ, the prevalence decreased to 14% (95% CI 8–23%), measured 10 weeks after the first
treatment. Based on POC-CCA, measured at the final follow-up time point, 82% (95% CI 72–
Fig 1. Trial profile. a. Sample (urine and/or stool) not provided. b. Intention-to-treat analysis.
https://doi.org/10.1371/journal.pntd.0008189.g001
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89%) and 64% (95% CI 54–74%) POC-CCA positives were observed in the standard and
intense treatment group, respectively.
Intensity of infection over time
The intensity of infection over time based on KK and POC-CCA is shown in Fig 3 (see also S2
Fig and S3 Fig). Based on the KK technique (Fig 3A and 3B), most of the remaining infections
after the first treatment were of low intensity. In the standard treatment group, the proportion
of low, moderate and, to a smaller extent, heavy intensity infections showed an increase 10
weeks after treatment. In the intense treatment group, a small proportion of infections of low
intensity were observed at the final time point. Based on POC-CCA (Fig 3C and 3D), the over-
all prevalence did not change dramatically and the proportion of 3+ scores (indicating high
infection level) remained similar over time in the standard treatment group as well as in the
intense treatment group. The proportion of POC-CCA negatives (including traces) increased
over time, particularly in the intense treatment group. In both groups, most children remained
POC-CCA positive at the final time point. A positive correlation was observed between fecal
egg counts and POC-CCA visual scores before treatment (Spearman’s rho = 0.44, P<0.01) (S4
Fig).
Table 1. Baseline characteristics of the standard treatment group and the intense treatment group in a random-
ized trial. The trial was conducted in late 2018 among school-aged children in south-central Coˆte d’Ivoire and com-
pared single versus four repeated PZQ treatments against S. mansoni.
Standard treatment group
(1x PZQ)
Intense treatment group
(4x PZQ)
N = 70 N = 83
Age, years 10.5 (9–12) 10.0 (9–12)
Weight, kg 32.2 (27.3–38.4) 32.0 (26.5–38.0)
Height, cm 137 (130–145) 140 (128–146)
Hemoglobin (g/dl) 11.3 (10.8–11.8) 11.3 (10.8–12.0)
Sex
Boys 43 (61.4%) 51 (61.4%)
Girls 27 (38.6%) 32 (38.6%)
Village
Ahouaty 35 (50.0%) 41 (49.4%)
N’Denou 27 (38.6%) 33 (39.8%)
Singrobo 8 (11.4%) 9 (10.8%)
Infection intensity
Kato-Katz
Light (1–99 EPG) 24 (34.3%) 35 (42.2%)
Moderate (100–399 EPG) 28 (40.0%) 36 (43.4%)
Heavy (�400 EPG) 18 (25.7%) 12 (14.4%)
POC-CCAa
1+ 16 (22.9%) 22 (26.5%)
2+ 38 (54.2%) 50 (60.2%)
3+ 16 (22.9%) 11 (13.3%)
Data are median (IQR) or n (%). Abbreviations: EPG, eggs per gram of stool; IQR, interquartile range; POC-CCA,
point-of-care circulating cathodic antigen.
a POC-CCA positive G-scores were classified into 1+ (G4-5), 2+ (G6-7) or 3+ (G8-10).
https://doi.org/10.1371/journal.pntd.0008189.t001
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Cure rate
In the standard treatment group, CR based on triplicate KK thick smears was 42% (95% CI
31–53%) (Table 2; see also S2 Table). A significantly higher CR (86%, 95% CI 75–92%) was
observed in the intense treatment group, (P<0.01; primary outcome, both CRs measured 10
weeks after first treatment). When using the same time interval post-treatment to compare
CRs between the two groups, i.e., four weeks after the first treatment for the standard treat-
ment group and four weeks after the fourth treatment for the intense treatment group, the
observed CR in the standard treatment group was 68% (95% 57–78%) compared to 86% (95%
CI 75–92%) in the intense treatment group (P<0.01).
POC-CCA-based CRs were much lower compared to CRs based on the KK technique; only
18% (95% CI 11–27%) in the standard treatment group and 36% (95% CI 26–46%) in the
intense treatment group (P<0.01). Using the 4-week post-treatment time points, CRs were
similar in both groups; 31% (95% CI 23–40%) in the standard treatment group and 36% (95%
CI 26–46%) in the intense treatment group (P = 0.23).
Intensity reduction rate
Based on the KK technique, the IRR in the standard treatment group was 72% (95% CI 55–
83%), compared to 95% (95% CI 85–98%) in the intense treatment group (P<0.01). When
using the same time interval post-treatment to compare IRRs between the two groups (4
weeks), the observed IRR in the standard treatment group was 83% (95% CI 69–91%) versus
95% (95% CI 85–98%) in the intense treatment group (P<0.01). The decrease in the mean
POC-CCA G-score was larger in the intense treatment group compared to the standard treat-
ment group, resulting in an IRR of 27% and 9%, respectively (measured 10 weeks after first
treatment). When using the same time interval post-treatment for the standard treatment
group, the IRR was 20%.
Fig 2. Prevalence over time (with corresponding pointwise 95% confidence intervals) estimated from the mixed effects logistic regression model. Data
pertain to (a) triplicate Kato-Katz (KK) thick smears from a single stool sample and (b) single point-of-care circulating cathodic antigen (POC-CCA) urine
test in the standard treatment group (single dose of PZQ, solid line) and the intense treatment group (four doses of PZQ at W0, W2, W4, and W6, dashed
line).
https://doi.org/10.1371/journal.pntd.0008189.g002
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Safety of PZQ
Observed and reported (within 3 hours) adverse events are summarized in Table 3, stratified
by treatment group and follow-up time point. After the first treatment, stomach ache was the
most common adverse event (overall 38%), followed by headache (overall 5%) and vomiting
(overall 3%). Most of the adverse events were mild and all of them resolved 24 hours after
Fig 3. Intensity of infection. Data are based on triplicate Kato-Katz (KK) thick smears from a single stool sample (a, b) and single point-of-care circulating
cathodic antigen (POC-CCA) urine test (c, d) in the standard treatment group (single dose of PZQ) and the intense treatment group (four doses of PZQ at W0,
W2, W4, and W6).
https://doi.org/10.1371/journal.pntd.0008189.g003
PLOS NEGLECTED TROPICAL DISEASES Effect of repeated praziquantel on Schistosoma mansoni
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0008189 March 20, 2020 10 / 19
Table 2. Cure rate (CR) and intensity reduction rate (IRR) of a single (standard treatment group) and four
(intense treatment group) repeated PZQ treatments in school-aged children infected with S. mansoni. Data are
based on triplicate Kato-Katz (KK) thick smears from a single stool sample and single point-of-care circulating
cathodic antigen (POC-CCA) urine test.
Standard treatment group
(1x PZQ)
N = 70
Intense treatment group
(4x PZQ)
N = 83
Kato-Katz
Infected children before treatment 70 83
Cured children 10 weeks after first treatment 28 69
CRa,b 41.6%
(95% CI 31.1–52.9%)
86.0%
(95% CI 75.4–92.4%)
Cured children 4 weeks post-treatmentc 47 69
CRb 68.2%
(95% CI 57.1–77.6%)
86.0%
(95% CI 75.4–92.4%)
Median EPGd
Before treatment 172 128
10 weeks after first treatment 64 8
4 weeks post-treatmentc 36 8
Arithmetic mean EPG
Before treatment 298.2 242.7
10 weeks after first treatment 97.7 3.2
IRRe 72.3%
(95% CI 54.6–83.1%)
95.1%
(95% CI 85.1–98.4%)
4 weeks post-treatmentc 45.8 3.2
IRRe 83.3%
(95% CI 68.9–91.2%)
95.1%
(95% CI 85.1–98.4%)
POC-CCA
Infected children before treatment 70 83
Cured children 10 weeks after first treatment 15 29
CRb 17.9%
(95% CI 11.3–27.2%)
35.7%
(95% CI 26.4–46.1%)
Cured children 4 weeks post-treatmentc 26 29
CRb 31.2%
(95% CI 23.4–40.2%)
35.7%
(95% CI 26.4–46.1%)
Median G-scored
Before treatment 6 7
10 weeks after first treatment 7 6
4 weeks post-treatmentc 6 6
Arithmetic mean G-score
Before treatment 6.4 6.3
10 weeks after baseline treatment 5.8 4.6
IRRf 9.3% 27.0%
4 weeks post-treatmentc 5.1 4.6
IRRf 20.3% 27.0%
Abbreviations: CR, cure rate; EPG. eggs per gram of stool; IRR, intensity reduction rate; POC-CCA, point-of-care
circulating cathodic antigen
a Primary outcome
b CR as calculated from the model
c Measured four weeks after first treatment for the standard treatment group, and four weeks after the fourth
treatment for the intense treatment group
d Median of the positives
e IRR based on the reduction in mean EPG as calculated from the model
f IRR based on the reduction in mean POC-CCA G-score as calculated manually
https://doi.org/10.1371/journal.pntd.0008189.t002
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treatment. Adverse events decreased with subsequent treatments in the intense treatment
group.
Discussion
Based on stool microscopy, we observed a significantly higher CR after four closely spaced
PZQ treatments compared to a single dose, measured 10 weeks after the first treatment, with-
out any difference in the frequency and severity of adverse events. Employing the POC-CCA
test, the observed CRs were considerably lower compared to KK, even after four repeated treat-
ments, indicating that worms are still present and that PZQ might be less efficacious than pre-
viously published.
Our aim of administering PZQ four times at 2-week intervals was to achieve a high CR, as
this approach not only targets adult schistosomes, but also the immature forms, which were
not yet drug-susceptible during the first treatment [12, 29, 42]. Indeed, 10 weeks after the base-
line survey, four repeated treatments resulted in a significantly higher CR than a single treat-
ment based on the KK technique, but failed to cure all infections. The primary outcome
according to the study protocol, i.e., the difference in CR of a single versus four repeated PZQ
treatments, was calculated by comparing the prevalence of infection at baseline and 10 weeks
after the first treatment [31]. This implied that the time interval after treatment was not the
same for both groups; 10 weeks after the single treatment in the standard treatment group
(allowing for a 10-week period of possible worm maturation, worm recovery, as well as
renewed parasite exposure and re-infection) versus four weeks after the fourth treatment in
the intense treatment group. To render the comparison between the groups more representa-
tive, CRs were also determined using the same time interval for both groups, i.e., for the stan-
dard treatment group taking four weeks after the first treatment as the final time point. While
the CR in the standard treatment group was significantly higher four weeks after treatment
compared to the CR obtained 10 weeks after treatment, there was no significant difference in
the CRs between the standard treatment group and the intense treatment group four weeks
after the last treatment, measured with both KK and POC-CCA. Hence, following this evalua-
tion approach, there is no indication that four repeated PZQ treatments outperform a single
treatment in curing schistosomiasis.
Moreover, although four repeated PZQ treatments resulted in a statistically significantly
higher CR when utilizing the KK technique compared to POC-CCA, the estimated CR was
considerably lower than what we had expected [31], and the proportion of KK-positives
Table 3. Main type of adverse events observed and reported 3 hours after PZQ administration in S. mansoni-infected children in the standard treatment group and
the intense treatment group.
Standard treatment
group
Intense
treatment group
First treatment
W0
First treatment
W0
Second treatment
W2
Third treatment
W4
Fourth treatment
W6
N = 70 N = 83 N = 82 N = 82 N = 78
Adverse events
Stomach ache 25 36% 33 40% 25 30% 22 27% 10 13%
Headache 3 4% 5 6% 14 17% 4 5% 2 3%
Vomiting 3 4% 2 2% 2 2% 4 5% 2 3%
Dizziness 2 3% 2 2% 3 4% 9 11% 6 8%
Diarrhea 2 3% 1 1% 0 0 0
Nausea 0 0 0 1 1% 1 1%
https://doi.org/10.1371/journal.pntd.0008189.t003
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increased again from 1% before the fourth treatment to 14% four weeks after the fourth treat-
ment. This might indicate continued parasite exposure, ongoing re-infection, and worm matu-
ration after treatment over the course of the study, not excluding possible PZQ resistance.
Compliance to treatment was very high at each treatment, most likely due to the relatively
mild and short-lived adverse events in combination with the commitment of the field and lab-
oratory team, and enthusiastic participation of children. At each treatment time point, directly
observed treatment was applied by the study physician. We therefore conclude that the
observed increase in proportion of KK-positives at the final time point in the intense treatment
group cannot be explained by the fact that some children might not have taken the (repeatedly)
administered drugs, but points to parasite survival in the host or rapid reinfection.
To more accurately assess the CR, the POC-CCA test was employed in addition to KK. CRs
based on POC-CCA were significantly lower in both groups compared to CRs based on the
KK technique. Even though the number of POC-CCA negatives increased after four treat-
ments, still more than half of the participants remained positive (traces conservatively consid-
ered as negative), indicating that active Schistosoma infections were still present in our cohort
or new infections occurred within short periods.
Previous studies have demonstrated false positive POC-CCA results in people with urinary
tract infections [43] as well as potentially in pregnant women [44] and new born babies. In our
study, no urinary tract infections were noted, two female participants were excluded because
of possible pregnancy, and only children aged 5 years and above were included. To further
minimize the inclusion of false positives, traces were considered as negative in our analysis.
Recent studies have shown that prevalence estimates of S. mansoni below 20% according to the
KK technique might correspond to POC-CCA prevalence estimates that are 3- to 4-fold higher
[18, 45]. Furthermore, studies applying latent class analysis to determine the performance of
diagnostic assays have shown that the POC-CCA test has a considerably greater sensitivity and
a comparable specificity than the KK technique, especially when traces are considered negative
[20, 46]. In contrast, other studies have shown that POC-CCA might be of limited use to diag-
nose S. mansoni infection, especially in low endemic areas [47]. More accurate diagnostic
methods, such as PCR [48, 49] or the upconverting phosphor lateral flow (UCP-LF) assay
detecting circulating anodic antigen [50], both being well established laboratory-based assays,
could be used to determine prevalence more accurately.
It is important to note that the two diagnostic methods employed in our study detect differ-
ent Schistosoma life-cycle stages, namely eggs in case of KK thick smears examined under a
microscope and antigens derived from adult worms in case of the POC-CCA urine test. Find-
ing a high proportion of individuals positive by POC-CCA after treatment, while no eggs are
detected by KK, indicates that the infection is not fully cured. Mature worms could have been
affected by PZQ but not killed, resulting in the (temporary) reduction or cessation of fecal egg
excretion [13], while still excreting CCA detectable by POC-CCA. Furthermore, individuals
can harbor living (single sex) worms with only sporadically excreting eggs in stool or with no
detectable eggs at all [51–54]. CCA might also originate from new infections or immature
worms [55] or perhaps from dead worms that were killed by PZQ. Lastly, PZQ treatment
could have resulted in a reduction of fecundity, indicating that egg-based diagnostic methods
will overestimate the reduction in worm burden [56, 57]. However, even with the presence of
low worm numbers, which excrete relatively few eggs, there is a continued risk of pathology
[58, 59], as eggs could retain in the host tissue, where they induce inflammatory responses
resulting in ‘subtle morbidity’ [60].
Little is known about the transmission of schistosomes in the study setting of south-central
Coˆte d’Ivoire; transmission is suspected to be ongoing, given the number of observed cases
and the frequent surface water contact of the inhabitants with the man-made Lake Taabo [27,
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30]. This trial focused on simply measuring the efficacy of PZQ and did not include sanitation
and behavioral interventions, which in this specific setting would have had an additional
impact on the number and intensity of Schistosoma infections. Moreover, since this study
focused on a subset of school-aged children, other children in the same age range, as well as
preschool-aged children or adolescents/adults from the community would still serve as a reser-
voir of infection and therefore contribute to ongoing transmission.
The CR and IRR as determined by the KK technique were higher after four treatments com-
pared to a single treatment, both at four and 10 weeks after treatment. This observation sug-
gests that repeated treatment has an added value on reducing the number of infections and
Schistosoma-related infection intensity and thus morbidity in areas where people are likely
infected with different developmental stages of the parasite and rapid re-infection is obvious.
However, since microscopy lacks sensitivity, especially in infections of low intensity and post-
treatment settings, not being able to detect eggs does not necessarily mean that the infection is
cured and that all worms have been killed. In contrast to the high IRR based on the KK tech-
nique, only a minor reduction in POC-CCA-based infection intensity was observed, which did
not increase significantly after four repeated PZQ treatments. This contradicts previous studies
that indicated a decrease in POC-CCA intensity score rapidly after treatment [20, 47, 61].
More accurate diagnostic methods, such as the UCP-LF CAA test or quantitative PCR could
be applied to more accurately determine the reduction in intensity.
Previous studies indicate that the frequency and severity of adverse events is related to
Schistosoma infection intensity, with more events reported in infections with a heavy intensity
[62, 63]. Over the course of the trial, mostly mild and short-lived adverse events were observed,
which presumably can be attributed to the relatively low intensity of infection in our study
population. Overall, repeated PZQ treatment was well tolerated, indicating that repeated PZQ
treatment can be considered as safe. Repeated PZQ treatment might help to enhance the con-
trol of schistosomiasis. This should not preclude the notion that treatment, whether single or
repeated, should always be combined with other control measures, such as behavior change,
sanitation, safe water, and snail control interventions in order to bolster the effect of PZQ and
to move toward interruption of transmission.
Conclusion
Based on stool microscopy using the KK technique, four repeated doses of 40 mg/kg PZQ at
2-week intervals resulted in a CR against S. mansoni infection of 86%, as determined 10 weeks
after the initial treatment. When using the more sensitive POC-CCA test, the observed CR was
significantly lower (27%), indicating that PZQ might not be as efficacious as previously
reported. The same trend is shown when efficacy is expressed as IRR, which highlights the rele-
vance of accurate diagnostic methods in monitoring treatment efficacy as well as other control
approaches (e.g. vaccine development).
This study signifies that the development and field implementation of reliable and more
accurate diagnostic tools are essential to systematically map transmission intensity and mea-
sure efficacy of control strategies, ultimately providing rational guidance on the path toward
elimination of schistosomiasis.
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